证券代码：300244 证券简称：迪安诊断 公告编号：2024-084 截至 2024 年 10 月 30 日，公司本次回购股份方案已实施完毕。现将有关情 况公告如下： 一、回购股份的实施情况 1、2024 年 3 月 8 日，公司首次通过回购专用证券账户以集中竞价交易方式 回购公司股份 311,600 股。具体内容详见公司于 2024 年 3 月 11 在巨潮资讯网披 露的《关于首次回购公司股份的公告》。 2、根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》的 规定，回购期间公司应当在每个月的前三个交易日内披露截至上月末的回购进展 情况。具体内容详见公司分别于 2024 年 3 月 4 日、2024 年 4 月 2 日、2024 年 5 月 7 日、2024 年 6 月 4 日、2024 年 7 月 2 日、2024 年 8 月 2 日、2024 年 9 月 4 日及 2024 年 10 月 9 日在巨潮资讯网披露的《关于回购公司股份的进展公告》。 3、根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》的 1 迪安诊断技术集团股份有限公司 关于回购公司股份实施完成暨股份变动的公 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown improvement in cash flow, with the ICL business expanding internationally, opening new opportunities [1] - The company reported a slight pressure on performance due to a complex industry environment, with a year-on-year revenue decline of 11.89% in Q3 [1] - The cash flow situation has improved, with a net cash flow from operating activities of 54 million, recovering from a negative cash flow in the previous half [1] Financial Performance Summary - For the first three quarters of 2024, the company achieved revenue of 92.58 billion, a year-on-year decrease of 10.1%, and a net profit attributable to shareholders of 1.31 billion, down 75.4% [1] - The gross profit margin for Q1 to Q3 2024 was 28.05%, an increase of 4.76 percentage points year-on-year, while the net profit margin was 3.27%, a decrease of 4.42 percentage points year-on-year [1] - The company’s revenue for Q3 was 30.40 billion, with a net profit of 0.59 billion, reflecting a year-on-year decline of 23.81% [1] Future Projections - The company is expected to achieve total revenue of 126.70 billion, 133.22 billion, and 142.51 billion for the years 2024, 2025, and 2026 respectively [2] - The projected net profit attributable to shareholders for the same years is 3.27 billion, 6.13 billion, and 8.10 billion, indicating a significant recovery in profitability [2] - The gross margin is expected to stabilize around 27.8% in 2024, with gradual improvements in subsequent years [3] Cash Flow and Financial Ratios - The operating cash flow is projected to improve to 1.92 billion in 2025 and 2.30 billion in 2026 [4] - The company’s debt levels are expected to decrease, with a net debt ratio projected to drop to 65.7% in 2024 and further to 48.8% by 2026 [6] - The return on equity (ROE) is anticipated to rise from 4.2% in 2024 to 8.8% in 2026, reflecting improved profitability [6]

证券代码：300244 证券简称：迪安诊断 公告编号：2024-083 迪安诊断技术集团股份有限公司 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 董事会 2024 年 10 月 29 日 附件： 马迅先生简历 马迅先生：保荐代表人，硕士研究生学历，现任中信建投证券股份有限公司 投资银行业务管理委员会副总裁，曾主持或参与的项目有：工大科雅 IPO、灿勤 科技 IPO、申昊科技 IPO、火星人 IPO、亚太科技 2023 年可转债、浙文互联 非公开、巨星科技 2020 年可转债、巨星科技重大资产购买、杭叉集团重大资产 购买等。 近日，公司收到中信建投出具《关于变更迪安诊断技术集团股份有限公司非 公开发行股票持续督导保荐代表人的函》，孔林杰先生因个人工作调动原因无法 继续履行持续督导职责，为保证对公司持续督导工作的正常进行，中信建投现指 派马迅先生（简历详见附件）接替孔林杰先生担任公司持续督导保荐代表人，继 续履行相关职责。 本次变更后，公司 2017 年非公开发行股票持续督导的保荐代表人为周伟先 生、马迅先生，持续督导期至中国 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report indicates that the company's fundamentals have bottomed out, with expectations for continued improvement in profitability and operating cash flow [1] - The company has faced challenges due to multiple factors including medical reforms, pricing adjustments, and market competition, but is expected to stabilize and recover in the future [1][2] - The report highlights a significant improvement in operating cash flow and effective management of accounts receivable, which is anticipated to continue [1] Financial Performance Summary - **Revenue Forecasts**: - 2022A: 20,282 million - 2023A: 13,408 million (down 34% YoY) - 2024E: 12,671 million (down 5% YoY) - 2025E: 12,965 million (up 2% YoY) - 2026E: 13,385 million (up 3% YoY) [1] - **Net Profit Forecasts**: - 2022A: 1,434 million - 2023A: 307 million (down 79% YoY) - 2024E: 335 million (up 9% YoY) - 2025E: 620 million (up 85% YoY) - 2026E: 885 million (up 43% YoY) [1] - **Earnings Per Share (EPS)**: - 2022A: 2.29 - 2023A: 0.49 - 2024E: 0.54 - 2025E: 0.99 - 2026E: 1.42 [1] - **Cash Flow**: - Operating cash flow is expected to improve significantly, with a net cash flow from operating activities of -0.12 billion in Q3 2024, indicating a recovery trend [1] Business Segment Performance - The report notes that the company's routine testing business is expected to see rapid growth, with a focus on enhancing its product offerings and stabilizing its market position [1] - The ICL business segment has shown a decline in revenue but is projected to stabilize as demand for diagnostic services recovers [1][2] Strategic Initiatives - The company is actively expanding its precision center strategy and accelerating its overseas operations, with new laboratories opening in Vietnam to tap into international markets [1][2] - The report emphasizes the importance of managing accounts receivable effectively to mitigate risks associated with bad debts [1]

Investment Rating - The report maintains a "Recommended" rating for the company [1]. Core Viewpoints - The company's diagnostic services continue to face pressure, with a significant impact on apparent performance due to impairment provisions. In Q3 2024, the company reported diagnostic service revenue of 1.155 billion, with ICL business revenue at 1.048 billion. The willingness to outsource remains affected by industry restructuring, rapid DRG advancement, and competition [1]. - The core strategic business is progressing steadily, with lean management contributing to future growth. The company has deepened its precision center, collaborative construction, discipline development, and group-level client expansion, adding 4 precision centers in Q3, totaling 84, with 52 achieving profitability in the same year. Q3 business revenue grew by 27.8% year-on-year [1]. - The company is a leading third-party medical testing service provider in China, with integrated "product + service" development. As the national layout improves, operational efficiency increases, and the proportion of special inspections rises, core business is expected to grow steadily in the long term. The profit forecast for 2024-2026 has been adjusted to 309 million, 612 million, and 861 million, with corresponding EPS of 0.49, 0.98, and 1.38 yuan, reflecting a PE of 26, 13, and 9 times for 2024-2026 [1]. Financial Summary - For the first nine months of 2024, the company achieved revenue of 9.258 billion (down 10.05%), net profit attributable to shareholders of 131 million (down 75.35%), and operating cash flow of 54 million (down 85.22%). Q3 2024 revenue was 3.040 billion (down 11.89%), with net profit of 59 million (down 23.81%) [1][4]. - The financial forecast indicates a revenue decline of 33.89% in 2023, followed by a projected decrease of 10.57% in 2024, with a gradual recovery expected in subsequent years [4][8].

Financial Performance - Revenue for the third quarter was RMB 3.04 billion, a decrease of 11.89% year-over-year[2] - Net profit attributable to shareholders was RMB 59.11 million, down 23.81% year-over-year[2] - Operating cash flow for the first nine months was RMB 54.2 million, a significant decrease of 85.22% year-over-year[2] - Total assets decreased by 4.81% to RMB 17.08 billion compared to the end of the previous year[2] - Net profit for the quarter decreased to 302.68 million yuan, down from 791.43 million yuan in the same period last year[18] - Sales revenue for the quarter was 9.42 billion yuan, compared to 11.78 billion yuan in the previous year[19] - Operating cash flow for the quarter was 54.20 million yuan, a significant drop from 366.81 million yuan in the same period last year[20] - The company's operating income for the current period was 9,258,110,867.57 yuan, compared to 10,292,194,930.88 yuan in the same period last year[17] - The company's operating costs for the current period were 8,491,254,006.48 yuan, compared to 8,977,566,104.97 yuan in the same period last year[17] Revenue Breakdown - Diagnostic services revenue reached RMB 1.155 billion, with ICL business contributing RMB 1.048 billion[5] - Channel product business revenue was RMB 1.912 billion, while proprietary product revenue was RMB 86 million[5] Expansion and Investments - The company added 4 new precision centers in Q3, bringing the total to 84, with 52 already profitable[6] - International expansion continued with the opening of a testing laboratory in Vietnam[6] - Long-term equity investments increased by 46.71% to RMB 983.57 million due to the acquisition of equity in an associate[5] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 39,463[7] - Chen Haibin, a domestic natural person, holds 26.31% of the shares, totaling 164,438,933 shares, with 123,329,200 shares under restricted sale[7] - Hong Kong Securities Clearing Corporation, an overseas legal entity, holds 3.90% of the shares, totaling 24,355,573 shares[7] - China Bank Limited - Huabao CSI Medical ETF holds 2.73% of the shares, totaling 17,079,326 shares[7] - Hangzhou Dian Holding Co., Ltd., a domestic non-state-owned legal entity, holds 1.70% of the shares, totaling 10,636,390 shares[7] - Xu Min, a domestic natural person, holds 1.60% of the shares, totaling 10,007,933 shares[7] - Morgan Stanley & Co. International PLC, an overseas legal entity, holds 0.78% of the shares, totaling 4,854,440 shares[7] - BNP Paribas - Own Funds, an overseas legal entity, holds 0.77% of the shares, totaling 4,793,600 shares[7] - Cai Ziwei, a domestic natural person, holds 0.74% of the shares, totaling 4,596,900 shares[7] Share Repurchase and Capital Reduction - As of September 30, 2024, the company has repurchased 13,406,000 shares, accounting for 2.14% of the total shares, with a total transaction amount of RMB 193,590,266[12] - The company plans to change the use of repurchased shares from "employee stock ownership plan or equity incentive" to "cancellation and corresponding reduction of registered capital," resulting in the cancellation of 1,918,600 shares and a reduction in total shares from 626,898,036 to 624,979,436[13] Financial Position - As of September 30, 2024, the company's monetary funds decreased to 1,370,982,095.00 yuan from 2,973,332,466.18 yuan at the beginning of the period[14] - The company's accounts receivable increased to 8,366,381,925.24 yuan from 8,054,200,551.87 yuan at the beginning of the period[15] - The company's inventory increased to 1,797,893,772.68 yuan from 1,508,948,754.81 yuan at the beginning of the period[15] - The company's total assets decreased to 17,075,684,838.18 yuan from 17,939,311,256.63 yuan at the beginning of the period[15] - The company's total liabilities decreased to 7,597,898,943.63 yuan from 8,034,531,783.60 yuan at the beginning of the period[16] Expenses and Income - R&D expenses decreased to 225.28 million yuan from 320.48 million yuan in the previous year[18] - Management expenses were reduced to 547.06 million yuan from 650.88 million yuan in the same period last year[18] - Investment income for the quarter was 9.18 million yuan, up from 632,086.78 yuan in the previous year[18] - Income tax expenses decreased by 47.18% to RMB 121.49 million due to lower profit[5] Cash Flow - Cash received from selling goods and providing services was 9.42 billion yuan, down from 11.78 billion yuan in the same period last year[19] - Cash paid for goods and services was 6.43 billion yuan, compared to 7.54 billion yuan in the previous year[20] - Cash paid to employees decreased to 1.62 billion yuan from 2.03 billion yuan in the same period last year[20] - Cash received from investment activities was 569.13 million yuan, down from 948.12 million yuan in the previous year[20] - Net cash flow from investment activities was -622.52 million yuan, a decrease of 85.5% compared to the previous period's -335.63 million yuan[21] - Cash received from investments was 53.12 million yuan, a decrease of 3.8% compared to the previous period's 55.20 million yuan[21] - Cash received from borrowings was 1.43 billion yuan, an increase of 37.5% compared to the previous period's 1.04 billion yuan[21] - Total cash inflow from financing activities was 1.66 billion yuan, an increase of 17.9% compared to the previous period's 1.41 billion yuan[21] - Cash paid for debt repayment was 1.53 billion yuan, a decrease of 41.5% compared to the previous period's 2.62 billion yuan[21] - Cash paid for dividends, profits, or interest payments was 654.08 million yuan, an increase of 62.5% compared to the previous period's 402.56 million yuan[21] - Total cash outflow from financing activities was 2.68 billion yuan, a decrease of 20.3% compared to the previous period's 3.36 billion yuan[21] - Net cash flow from financing activities was -1.02 billion yuan, an improvement of 47.7% compared to the previous period's -1.96 billion yuan[21] - Net increase in cash and cash equivalents was -1.60 billion yuan, an improvement of 17.1% compared to the previous period's -1.93 billion yuan[21] - Ending balance of cash and cash equivalents was 1.35 billion yuan, a decrease of 39.1% compared to the previous period's 2.22 billion yuan[21] Shareholder Pledges - The company's actual controller, Mr. Chen Haibin, and his concerted parties have pledged a cumulative 18.40% of the company's total shares, accounting for 65.69% of their holdings as of September 30, 2024[13]

证券代码：300244 证券简称：迪安诊断 公告编号：2024-079 迪安诊断技术集团股份有限公司 关于2024年半年度权益分派实施后 调整回购股份价格上限的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、回购股份的基本情况 迪安诊断技术集团股份有限公司（以下简称"公司"）于2024年2月6日召开 第五届董事会第四次会议审议通过了《关于回购公司股份方案的议案》，同意 使用自有资金以集中竞价交易方式回购公司人民币普通股A股股份（以下简称 "本次回购"），用于实施员工持股计划或者股权激励。回购金额不低于人民币 10,000万元（含）且不超过人民币20,000万元（含），回购价格不超过人民币 27.94元/股（含），回购期限自董事会审议通过本次回购股份方案之日起12个月 内。具体内容详见公司于2024年2月7日在巨潮资讯网披露的《关于回购公司股 份方案的公告》《回购报告书》以及公司于2024年6月12日在巨潮资讯网披露的 《关于2023年年度权益分派实施后调整回购股份价格上限的公告》。 二、2024年半年度权益分派方案实施情况 公司实施2024年半年度权 ...

证券代码：300244 证券简称：迪安诊断 公告编号：2024-080 迪安诊断技术集团股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 迪安诊断技术集团股份有限公司（以下简称"公司"）于2024年2月6日召开 第五届董事会第四次会议审议通过了《关于回购公司股份方案的议案》，同意 使用自有资金以集中竞价交易方式回购公司人民币普通股A股股份（以下简称 "本次回购"），用于实施员工持股计划或者股权激励。回购金额不低于人民币 10,000万元（含）且不超过人民币20,000万元（含），回购价格不超过人民币 27.30元/股（含），回购期限自董事会审议通过本次回购股份方案之日起12个月 内。具体内容详见公司于2024年2月7日在巨潮资讯网披露的《关于回购公司股 份方案的公告》《回购报告书》以及公司分别于2024年6月12日、2024年10月9 日在巨潮资讯网披露的《关于2023年年度权益分派实施后调整回购股份价格上 限的公告》《关于2024年半年度权益分派实施后调整回购股份价格上限的公 告》。 根据《上市公司股份回购规则》《深圳 ...

证券代码：300244 证券简称：迪安诊断 公告编号：2024-077 迪安诊断技术集团股份有限公司 第五届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪安诊断技术集团股份有限公司（以下简称"公司"）第五届董事会第十次会 议于 2024 年 9 月 27 日上午 10 点以通讯表决方式召开，本次会议的通知已于 2024 年 9 月 25 日通过电话、电子邮件等方式送达全体董事。本次会议由董事长陈海 斌先生主持，会议应出席董事 9 名，实际出席董事 9 名，符合《公司法》和《公 司章程》的规定。 会议审议通过了如下议案： 一、《关于出售控股子公司股权暨关联交易的议案》 2024 年 9 月 26 日公司及公司控股子公司苏州瀛凯欣运企业管理咨询有限公 司分别与杭州泰格医药科技股份有限公司（以下简称"泰格医药"）就上海观合 医药科技股份有限公司、诸暨观鹤企业管理合伙企业（有限合伙）、诸暨观荷三 期企业管理合伙企业（有限合伙）、诸暨观合四期企业管理合伙企业（有限合伙） 的股权或财产份额转让事项签署《股权转让协议》及《财产份额转让协议》，协 ...

2024 年 9 月 26 日公司及公司控股子公司苏州瀛凯欣运企业管理咨询有限公 司分别与杭州泰格医药科技股份有限公司（以下简称"泰格医药"）就上海观合 医药科技股份有限公司、诸暨观鹤企业管理合伙企业（有限合伙）、诸暨观荷三 期企业管理合伙企业（有限合伙）、诸暨观合四期企业管理合伙企业（有限合伙） 的股权或财产份额转让事项签署《股权转让协议》及《财产份额转让协议》，协 议约定公司及苏州瀛凯拟以现金方式转让其直接或间接所持观合医药合计 40.5650%股权，转让价格合计为人民币 14,036.41 万元。 证券代码：300244 证券简称：迪安诊断 公告编号：2024-078 迪安诊断技术集团股份有限公司 第五届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2024 年 9 月 27 日上午 10 点，迪安诊断技术集团股份有限公司（以下简称"公 司"或"迪安诊断"）以通讯表决方式召开了第五届监事会第七次会议，会议通知 已于 2024 年 9 月 25 日通过短信、电子邮件等方式送达全体监事。会议由公司监 事会主席师玉鹏先生召集和主持。 ...